-
1Academic Journal
Authors: M. I. Sokolova, V. I. Pavlova, A. O. Guz, A. V. Simonov, М. И. Соколова, В. И. Павлова, А. О. Гузь, А. В. Симонов
Source: Head and Neck Tumors (HNT); Том 14, № 3 (2024); 41-48 ; Опухоли головы и шеи; Том 14, № 3 (2024); 41-48 ; 2411-4634 ; 2222-1468
Subject Terms: общая выживаемость, squamous cell carcinoma of the oropharynx, expression of р16, expression of programmed death-ligand 1, overall survival, плоскоклеточный рак ротоглотки, экспрессия р16, экспрессия лиганда рецептора программируемой клеточной гибели 1
File Description: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/1003/641; Global Burden of Disease Cancer. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol 2019;5(12):1749–68. DOI:10.1001/jamaoncol.2019.2996; Adjei Boakye E., Buchanan P., Hinyard L. et al. Incidence and risk of second primary malignant neoplasm after a first head and neck squamous cell carcinoma. JAMA Otolaryngolog Head Neck Surg 2018;144(8):727–37. DOI:10.1001/jamaoto.2018.0993; Faisal M., Le N.S., Grasl S. et al. Survival outcome in true carcinoma of unknown primary (tCUP) with p16 + сervical metastasis. Int Arch Otorhinolaryngol 2023(27):e687–93. DOI:10.1055/s-0042-1759575; Conway A.M., Mitchell C., Kilgour E. et al. Molecular characterisation and liquid biomarkers in carcinoma of unknown primary (CUP): taking the “U” out of “CUP.” Br J Cancer 2019;120(2):141–53.; Pavlidis N., Pentheroudakis G. Cancer of unknown primary site. Lancet 2012;379(9824):1428–35. DOI:10.1016/S0140-6736(11)61178-1; Sivars L., Bersani C., Grün N. et al. Human papillomavirus is a favourable prognostic factor in cancer of unknown primary in the head and neck region and in hypopharyngeal cancer. Mol Clin Oncol 2016;5(6):671–4. DOI:10.3892/mco.2016.1050; Rassy E., Nicolai P., Pavlidis N. Comprehensive management of HPV-related squamous cell carcinoma of the head and neck of unknown primary. Head Neck 2109;41(10):3700–11. DOI:10.1002/hed.25858; Müller von der Grün J., Tahtali A., Ghanaati S. et al. Diagnostic and treatment modalities for patients with cervical lymph node metastases of unknown primary site – current status and challenges. Radiat Oncol 2017;12(1):82. DOI:10.1186/s13014-017-0817-9; Burtness B., Harrington K.J., Greil R. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;394(10212):1915–28. DOI:10.1016/S0140-6736(19)32591-7; Eskander A., Ghanem T., Agrawal A. et al. AHNS series: do you know your guidelines? Guideline recommendations for head and neck cancer of unknown primary site. Head Neck 2018;40(3):614–21. DOI:10.1002/hed.25026; Ren J., Yang W., Su J. et al. Human papillomavirus and p16 immunostaining, prevalence and prognosis of squamous carcinoma of unknown primary in the head and neck region Int J Cancer 2019;145:1465–74.; Kansy B.A., Concha-Benavente F., Srivastava R.M. et al. PD-1 status in CD8(+) T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer. Cancer Res 2017;77(22):6353–64. DOI:10.1158/0008-5472.CAN-16-3167; Mandal R., Şenbabaoğlu Y., Desrichard A. et al. The head and neck cancer immune landscape and its immunotherapeutic implications. JCI Insight 2016;1(17):e89829. DOI:10.1172/jci.insight.89829; Cohen E.E.W., Bell R.B., Bifulco C.B. et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer 2019;7(1):184. DOI:10.1186/s40425-019-0662-5; Binnewies M., Roberts E.W., Kersten K. et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med 2018;24(5):541–50. DOI:10.1038/s41591-018-0014-x; Elbehi A.M., Anu R.I., Ekine-Afolabi B., Cash E. Emerging role of immune checkpoint inhibitors and predictive biomarkers in head and neck cancers. Oral Oncol 2020;109:104977. DOI:10.1016/j.oraloncology.2020.104977; Patel J.J., Levy D.A., Nguyen S.A. et al. Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinomaSystematic review and meta-analysis. Head Neck 2020;42(4):774–86. DOI:10.1002/hed.26036; Haratani K., Hayashi H., Takahama T. et al. Clinical and immune profiling for cancer of unknown primary site. J Immunother Cancer 2019;7(1):25. DOI:10.1186/s40425-019-0720-z; Dong P., Xiong Y., Yue J. et al. Tumor-intrinsic PD-L1 signaling in cancer initiation, development and treatment: beyond immune evasion. Front Oncol 2018;8:386. DOI:10.3389/fonc.2018.00386; Simsek M., Tekin S.B., Bilici M. Immunological agents used in cancer treatment. Eurasian J Med 2019;51(1):90–4. DOI:10.5152/eurasianjmed.2018.18194; Alsahafi E., Begg K., Amelio I. et al. Clinical update on head and neck cancer: molecular biology and ongoing challenges. Cell Death Dis 2019;10(8):540. DOI:10.1038/s41419-019-1769-9; Hemminki K., Pavlidis N., Tsilidis K.K. et al. Age-dependent metastatic spread and survival: cancer of unknown primary as a model. Sci Rep 2016;6:23725. DOI:10.1038/srep23725; Cohen E.E., LaMonte S.J., Erb N.L. et al. American Cancer Society head and neck cancer survivorship care guideline. CA Cancer J Clin 2016;66(3):203–39. DOI:10.3322/caac.21343; Cummings M.A., Ma S.J., Van Der Sloot P. et al. Squamous cell carcinoma of the head and neck with unknown primary: trends and outcomes from a hospital-based registry. Ann Transl Med 2021;9(4):284. DOI:10.21037/atm-20-4631; Reuschenbach M., Tinhofer I., Wittekindt C. et al. A systematic review of the HPV-attributable fraction of oropharyngeal squamous cell carcinomas in Germany. Cancer Med 2019;8(4):1908–18. DOI:10.1002/cam4.2039; Sprave T., Rühle A., Hees K. et al. Radiotherapeutic management of cervical lymph node metastases from an unknown primary site – experiences from a large cohort treated with modern radiation techniques. Radiat Oncol 2020;15(1):80. DOI:10.1186/s13014-020-01529-z; Chung C.H., Zhang Q., Kong C.S. et al. p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J Clin Oncol 2014;32(35):3930–8. DOI:10.1200/JCO.2013.54.5228; https://ogsh.abvpress.ru/jour/article/view/1003
-
2Academic Journal
Authors: A. V. Ignatova, Yu. V. Alymov, А. В. Игнатова, Ю. В. Алымов
Source: Head and Neck Tumors (HNT); Том 14, № 1 (2024); 39-48 ; Опухоли головы и шеи; Том 14, № 1 (2024); 39-48 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2024-14-1
Subject Terms: ниволумаб, head and neck squamous cell carcinoma, oropharyngeal squamous cell carcinoma, targeted therapy, immunotherapy, programmed death-ligand 1, pembrolizumab, nivolumab, плоскоклеточный рак головы и шеи, плоскоклеточный рак ротоглотки, таргетная терапия, иммунотерапия, лиганд рецептора программируемой клеточной гибели 1, пембролизумаб
File Description: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/967/618; De Sanjose S., Quint W.G., Alemany L. et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010;11(11):1048—56. DOI:10.1016/S1470-2045(10)70230-8; Chaturvedi A.K., Engels E.A., Pfeiffer R.M. et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011;29(32):4294-301. DOI:10.1200/JCO.2011.36.4596; Nasman A., Attner P., Hammarstedt L. et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 2009;125(2):362-6. DOI:10.1002/ijc.24339; Gillison M.L., Broutian T., Pickard R.K. et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012;307(7):693-703. DOI:10.1001/jama.2012.101; Mehanna H., Beech T., Nicholson T. et al. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer - systematic review and meta-analysis of trends by time and region. Head Neck 2013;35(5):747-55. DOI:10.1002/hed.22015; Marklund L., Holzhauser S., de Flon C. et al. Survival of patients with oropharyngeal squamous cell carcinomas (OPSCC) in relation to TNM 8 - risk of incorrect downstaging of HPV-mediated non- tonsillar, non-base of tongue carcinomas. Eur J Cancer 2020;139:192-200. DOI:10.1016/j.ejca.2020.08.003; Gillison M.L., Koch W.M., Capone R.B. et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92(9):709-20. DOI:10.1093/jnci/92.9.709; Amin M., Edge S., Greene F. et al. AJCC Cancer Staging Manual, 8th edn. New York: Springer, 2017.; Masterson L., Moualed D., Liu Z.W. et al. De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma: a systematic review and meta-analysis of current clinical trials. Eur J Cancer 2014;50(15):2636-48. DOI:10.1016/j.ejca.2014.07.001; Economopoulou P., Kotsantis I., Psyrri A. Special issue about head and neck cancers: HPV positive cancers. Int J Mol Sci 2020;21(9):3388. DOI:10.3390/ijms21093388; Gillison M.L., Trotti A.M., Harris J. et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 2019;393(10166):40-50. DOI:10.1016/s0140-6736(18)32779-x; Liu C., Mann D., Sinha U.K., Kokot N.C. The molecular mechanisms of increased radiosensitivity of HPV-positive oropharyngeal squamous cell carcinoma (OPSCC): an extensive review. J Otolaryngol Head Neck Surg 2018;47(1):59. DOI:10.1186/s40463-018-0302-y; Ang K.K., Harris J., Wheeler R. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363(1):24-35. DOI:10.1056/NEJMoa0912217; Posner M.R., Lorch J.H., Goloubeva O. et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 2011;22(5):1071-7. DOI:10.1093/annonc/mdr006; Roselló À., Albuquerque R., Roselló-Llabrés X. et al. Transoral robotic surgery vs open surgery in head and neck cancer. A systematic review of the literature. Med Oral Patol Oral Cir Bucal 2020;25(5):e599-607. DOI:10.4317/medoral.23632; Economopoulou P., De Bree R., Kotsantis I., Psyrri A. Diagnostic tumor markers in head and neck squamous cell carcinoma (HNSCC) in the clinical setting. Front Oncol 2019;9:827. DOI:10.3389/fonc.2019.00827; Bossi P., Miceli R., Benasso M. et al. Impact of treatment expertise on the outcome of patients with head and neck cancer treated within 6 randomized trials. Head Neck 2018;40(12):2648-56. DOI:10.1002/hed.25389; Szturz P., Wouters K., Kiyota N. et al. Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data. Oncologist 2017;22(9):1056-66. DOI:10.1634/theoncologist.2017-0015; Vermorken J.B., Mesia R., Rivera F. et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11):1116-27. DOI:10.1056/NEJMoa0802656; Mehanna H., Robinson M., Hartley A. et al. On behalf of the de-escalate HPV trial group. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus - positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet 2019;393(10166):51-60. DOI:10.1016/S0140-6736(18)32752-1; Gleber-Netto F.O., Rao X., Guo T. et al. Variations in HPV function are associated with survival in squamous cell carcinoma. JCI Insight 2019;4(1):e124762. DOI:10.1172/jci.insight.124762; Brennan S., Baird A.M., O'Regan E., Sheils O. The role of human papilloma virus in dictating outcomes in head and neck squamous cell carcinoma. Front Mol Biosci 2021;8:677900. DOI:10.3389/fmolb.2021.677900; Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517(7536):576-82. DOI:10.1038/nature14129; Reder H., Wagner S., Gamerdinger U. et al. Genetic alterations in human papillomavirus-associated oropharyngeal squamous cell carcinoma of patients with treatment failure. Oral Oncol 2019;93:59-65. DOI:10.1016/j.oraloncology.2019.04.013; Harbison R.A., Kubik M., Konnick E.Q. et al. The mutational landscape of recurrent versus nonrecurrent human papillomavirus- related oropharyngeal cancer. JCI Insight 2018;3(14):e99327. DOI:10.1172/jci.insight.99327; Isaacsson Velho P.H., Castro G., Chung C.H. Targeting the PI3K pathway in head and neck squamous cell carcinoma. Am Soc Clin Oncol Educ Book 2015:123-8. DOI:10.14694/EdBook_AM.2015.35.123; Lechien J.R., Seminerio I., Descamps G. et al. Impact of HPV infection on the immune system in oropharyngeal and non- oropharyngeal squamous cell carcinoma: a systematic review. Cells 2019;8(9):1061. DOI:10.3390/cells8091061; Turksma A.W., Bontkes H.J., van den Heuvel H. et al. Effector memory T-cell frequencies in relation to tumour stage, location and HPV status in HNSCC patients. Oral Dis 2013;19(6):577-84. DOI:10.1111/odi.12037; Kareer R., Ahuja S., Chaudhary N., Arora R. Association of PD-L1 and p16 expression with clinicopathological parameters in oral cavity and oropharyngeal squamous cell carcinoma. Pathol Res Pract 2023;241:154266. DOI:10.1016/j.prp.2022.154266; Machiels J.P., Rene Leemans C., Golusinski W. et al. Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31(11):1462-75. DOI:10.1016/j.annonc.2020.07.011; Mandal R., §enbabaoglu Y., Desrichard A. et al. The Head and Neck Cancer Immune Landscape and its Immunotherapeutic Implications. JCI Insight 2016;1(17):e89829. DOI:10.1172/jci.insight.89829; Wang Y., Xu Y., Hua Q. et al. Novel prognostic model based on im-mune signature for head and neck squamous cell carcinoma. BioMed Res Int 2020;2020:4725314. DOI:10.1155/2020/4725314; Zhang F., Liu Y., Yang Y., Yang K. Development and Validation of a fourteen-innate immunity-related gene pairs signature for predicting prognosis head and neck squamous cell carcinoma. BMC Cancer 2020;20(1):1015. DOI:10.1186/s12885-020-07489-7; Varilla V., Atienza J., Dasanu C.A. Immune alterations and immunotherapy prospects in head and neck cancer. Expert Opin Biol Ther 2013;13(9):1241-56. DOI:10.1517/14712598.2013.810716; Wang H., Zhao Q., Zhang Y. et al. Immunotherapy advances in locally advanced and recurrent/metastatic head and neck squamous cell carcinoma and its relationship with human papillomavirus. Front Immunol 2021;12:652054. DOI:10.3389/fimmu.2021.652054; Clancy K., Hamill C.S., O'Neill W.Q. et al. Impact of p16 status and anatomical site in anti-PD-1 immunotherapy-treated recurrent/ metastatic head and neck squamous cell carcinoma patients. Cancers (Basel) 2021;13(19):4861. DOI:10.3390/cancers13194861; Kanaan H., Kourie H.R., Awada A.H. Are virus-induced cancers more sensitive to checkpoint inhibitors? Future Oncol 2016;12(23):2665-8. DOI:10.2217/fon-2016-028; Näsman A., Romanitan M., Nordfors C. et al. Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PLoS One 2012;7(6):e38711. DOI:10.1371/journal.pone.0038711; Green V.L., Michno A., Stafford N.D., Greenman J. Increased prevalence of tumour infiltrating immune cells in oropharyngeal tumours in comparison to other subsites: relationship to peripheral immunity. Cancer Immunol Immunother 2013;62(5):863-73. DOI:10.1007/s00262-013-1395-9; Matlung S.E., Wilhelmina van Kempen P.M., Bovenschen N. et al. Differences in T-cell infiltrates and survival between HPV+ and HPV- oropharyngeal squamous cell carcinoma. Future Sci OA 2016;2(1):Fso88. DOI:10.4155/fso.15.88; Welters M.J.P., Ma W., Santegoets S. et al. Intratumoral HPV16- specific T cells constitute a type i-oriented tumor microenvironment to improve survival in HPV16-driven oropharyngeal cancer. Clin Cancer Res 2018;24(3):634-47. DOI:10.1158/1078-0432.CCR-17-2140; Heusinkveld M., Goedemans R., Briet R.J. et al. Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer. Int J Cancer 2012;131(2):E74-85. DOI:10.1002/ijc.26497; Wood O., Woo J., Seumois G. et al. Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors. Oncotarget 2016;7(35):56781-97. DOI:10.18632/oncotarget.10788; Schoenfeld J.D., Gjini E., Rodig S.J. et al. Evaluating the PD-1 axis and immune effector cell infiltration in oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2018;102(1):137-45. DOI:10.1016/j.ijrobp.2018.05.002; Oliveira-Costa J.P., de Carvalho A.F., da Silveira G.G. et al. Gene expression patterns through oral squamous cell carcinoma development: PD-L1 expression in primary tumor and circulating tumor cells. Oncotarget 2015;6(25):20902-20. DOI:10.18632/oncotarget.3939; Lyford-Pike S., Peng S., Young G.D. et al. Evidence for a Role of the PD-1:PD-L1 pathway in immune resistance of HPV- associated head and neck squamous cell carcinoma. Cancer Res 2013;73(6):1733-41. DOI:10.1158/0008-5472.CAN-12-2384; Green S.E., McCusker M.G., Mehra R. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers. Expert Opin Emerg Drugs 2020;25(4):501-14. DOI:10.1080/14728214.2020.1852215; Sunshine J., Taube J.M. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 2015;23:32-8. DOI:10.1016/j.coph.2015.05.011; Ferris R.L., Blumenschein G., Fayette J. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375(19):1856-67. DOI:10.1056/NEJMoa1602252; Gulley J.L., Repasky E.A., Wood L.S., Butterfield L.H. Highlights of the 31st Annual Meeting of the Society for Immunotherapy of Cancer (Sitc), 2016. J Immunother Cancer 2017;5(1):55. DOI:10.1186/s40425-017-0262-1; Adusumilli P.S., Cha E., Cornfeld M. et al. New cancer immunotherapy agents in development: a report from an associated program of the 31st annual meeting of the Society for Immunotherapy of Cancer, 2016. J Immunother Cancer 2017;5:50. DOI:10.1186/s40425-017-0253-2; Massarelli E., William W., Johnson F. et al. Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: a phase 2 clinical trial. JAMA Oncol 2019;5(1):67-73. DOI:10.1001/jamaoncol.2018.4051; Seiwert T.Y., Burtness B., Mehra R. et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016;17(7):956-65. DOI:10.1016/S1470-2045(16)30066-3; Cohen E.E.W., Soulieres D., Le Tourneau C. et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019;393(10167):156-67. DOI:10.1016/S0140-6736(18)31999-8; Soulieres D., Harrington K.J., Le Tourneau C. et al. Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/ metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040. Ann Oncol 2022;33(Suppl_7):S295-322. DOI:10.1016/annonc/annonc1056; Burtness B., Harrington K.J., Greil R. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019;394(10212):1915-28. DOI:10.1016/s0140-6736(19)32591-7; Harrington K.J., Burtness B., Greil R. et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: updated results of the phase III KEYNOTE-048 study. JCO 2023;41(4):790-802. DOI:10.1200/JCO.21.02508.; Colevas A.D., Bahleda R., Braiteh F. et al. Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial. Ann Oncol. 2018;29(11):2247—53. DOI:10.1093/annonc/mdy411; Prendergast G.C., Malachowski W.J., Mondal A. et al. Indoleamine 2,3-dioxygenase and its therapeutic inhibition in cancer. Int Rev Cell Mol Biol 2018;336:175-203. DOI:10.1016/bs.ircmb.2017.07.004; Godin-Ethier J., Hanafi L.A., Piccirillo C.A., Lapointe R. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 2011;17(22): 6985-91. DOI:10.1158/1078-0432.CCR-11-1331; Nayak-Kapoor A., Hao Z., Sadek R. et al. Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors. J Immunother Cancer 2018;6(1):61. DOI:10.1186/s40425-018-0351-9; Mitchell T.C., Hamid O., Smith D.C. et al. Epacadostat plus pembrolizumab in patients with advanced solid tumors: phase I results from a multicenter, open-label phase i/ii trial (ECHO-202/ KEYNOTE-037). J Clin Oncol 2018;36(32):3223-30. DOI:10.1200/JCO.2018.78.9602; Outh-Gauer S., Alt M., Le Tourneau C. et al. Immunotherapy in head and neck cancers: a new challenge for immunologists, pathologists and clinicians. Cancer Treat Rev 2018;65:54-64. DOI:10.1016/j.ctrv.2018.02.008; Yearley J., Gibson C., Yu N. et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res 2017;23:(12):3158-67. DOI:10.1158/1078-0432.CCR-16-1761; Stanley M. HPV-immune response to infection and vaccination. Infect Agent Cancer 2010;5:19. DOI:10.1186/1750-9378-5-19; Whiteside T.L. Immune responses to cancer: are they potential biomarkers of prognosis? Front Oncol 2013;3:107. DOI:10.3389/fonc.2013.00107; Nguyen N., Bellile E., Thomas D. et al. Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma. Head Neck 2016;38(7):1074-84. DOI:10.1002/hed.24406; Chow L.Q.M., Haddad R., Gupta S. et al. Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol 2016;34(32):3838-45. DOI:10.1200/jco.2016.68.1478; Bauml J., Seiwert T.Y., Pfister D.G. et al. Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study. J Clin Oncol 2017;35(14):1542-9. DOI:10.1200/JCO.2016.70.1524; Pfister D.G., Haddad R.I., Worden F.P. et al. Biomarkers predictive of response to pembrolizumab in head and neck cancer. Cancer Med 2023;12(6):6603-14. DOI:10.1002/cam4.5434; Kumar B., Cordell K.G., Leeet J.S. al. EGFR, p16, HPV titer, Bcl-xL and p53, sex, and Smoking as indicators of response to therapy and survival in oropharyngeal cancer. JCO 2008;26(19):3128-37. DOI:10.1200/JCO.2007.12.7662; Sato F., Ono T., Kawahara A. et al. Prognostic impact of p16 and PD-L1 expression in patients with oropharyngeal squamous cell carcinoma receiving a definitive treatment. J Clin Pathol 2019;72(8):542-9. DOI:10.1136/jclinpath-2019-205818; Galvis M.M., Borges G.A., Oliveira T.B. et al. Immunotherapy improves efficacy and safety of patients with HPV positive and negative head and neck cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2020;150:102966. DOI:10.1016/j.critrevonc.2020.102966; https://ogsh.abvpress.ru/jour/article/view/967
-
3Academic Journal
Authors: T. Braunschweig, A. Lewandrowski, D. Smeets, M. V. Bolotin, Т. Брауншвейг, А. Левандровски, Д. Смеетс, М. В. Болотин
Source: Head and Neck Tumors (HNT); № 3 (2013); 4-10 ; Опухоли головы и шеи; № 3 (2013); 4-10 ; 2411-4634 ; 2222-1468 ; 10.17650/2222-1468-2013-0-3
Subject Terms: p16, head and neck, HNSCC, OPSCC, HPV, mutations, trial, p16 INK4A, голова и шея, плоскоклеточный рак головы и шеи, плоскоклеточный рак ротоглотки, вирус папилломы человека, мутации, исследование
File Description: application/pdf
Relation: https://ogsh.abvpress.ru/jour/article/view/11/13; Haddad R.I. and D.M. Shin. Recent advances in head and neck cancer. N Engl J Med 2008;359(11):1143–54.; Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60(5):277–300.; Brennan J.A., Boyle J.O., Koch W.M. et al. Association between cigarette smoking and mutation of the p53 gene in squamouscell carcinoma of the head and neck. N Engl J Med 1995;332(11):712–7.; Syrjanen K., Syrjanen S. and Pyrhonen S. Human papilloma virus (HPV) antigens in lesions of laryngeal squamous cell carcinomas. ORL J Otorhinolaryngol Relat Spec 1982;44(6):323–34.; Syrjanen K.J. and Surjanen S.M. Histological evidence for the presence of condylomatous epithelial lesions in association with laryngeal squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec 1981;43(4):181–94.; Quintero K., Giraldo G.A., Uribe M.L. et al. Human papillomavirus types in cases of squamous cell carcinoma of head and neck in Colombia. Braz J Otorhinolaryngol 2013;79(3):375–81.; Curado M.P. and Boyle P. Epidemiology of head and neck squamous cell carcinoma not related to tobacco or alcohol. Curr Opin Oncol 2013;25(3):229–34.; van Monsjou H.S., van Velthuysen M.L., van den Brekel M.W. et al. Human papillomavirus status in young patients with head and neck squamous cell carcinoma. Int J Cancer 2012;130(8):1806–12.; Smeets D., Ertmer K., Braunschweig T., Bolotin M.V. HPV in squamous epithelial lesions of the head and neck: different affection of different tumors. Tumors of the head and neck (in russian) 2011;1:61–5.; Thomas J. and Primeaux T. Is p16 immunohistochemistry a more cost-effective method for identification of human papilloma virus-associated head and neck squamous cell carcinoma? Ann Diagn Pathol 2012;16(2): 91–9.; National Cancer Registry Ireland Cancer Trends, 2011.10.; Kelley M.J., Otterson G.A. et al. CDKN2 in HPV-positive and HPV-negative cervical-carcinoma cell lines. Int J Cancer 1995;63(2):226–30.; Klaes R., Friedrich T., Spitkovsky D. et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92(2):276–84.; Mardis E.R. Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet 2008;9:387–402.; Lechner M., Frampton G., Fenton T. et al. Targeted next-generation sequencing of head and neck squamous cell carcinoma identifies novel genetic alterations in HPV+ and HPV- tumors. Genome Med 2013;5(5):49.; Stransky N., Egloff A.M., Tward A.D. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011;333(6046):1157–60.; Comprehensive genomic characterization of squamous cell lung cancers. Cancer Genome Atlas Research Network. Nature 2012;489(7417):519–25.; Bissada E., Abboud O., Abou Chacra Z. et al. Prevalence of K-RAS Codons 12 and 13 Mutations in Locally Advanced Head and Neck Squamous Cell Carcinoma and Impact on Clinical Outcomes. Int J Otolaryngol 2013;2013:848021.; Leemans C.R., Braakhuis B.J. and Brakenhoff R.H. The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11(1):9–22.; Schlecht N.F., Brandwein-Gensler M., Nuovo G.J. et al. A comparison of clinically utilized human papillomavirus detection methods in head and neck cancer. Mod Pathol 2011;24(10): 1295–305.; El-Naggar A.K. and Westra W.H. p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: A guide for interpretative relevance and consistency. Head Neck 2012;34(4):459–61.; Specenier P. and Vermorken J.B. Cetuximab: its unique place in head and neck cancer treatment. Biologics 2013;7:77–90.; Granata R., Miceli R., Orlandi E. et al. Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. Ann Oncol 2012;23(7):1832–7.; Chen Y.J., Rau K.M., Chien C.Y. et al. High p16 expression predicts a positive response to chemoradiotherapy in stage IVa/b head and neck squamous cell carcinoma. Asian Pac J Cancer Prev 2011;12(3):649–55.; Fischer C.A., Kampmann M., Zlobec I. et al. p16 expression in oropharyngeal cancer: its impact on staging and prognosis compared with the conventional clinical staging parameters. Ann Oncol 2010;21(10):1961–6.; Press O.W., Appelbaum F., Ledbetter J.A. et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 1987;69(2):584–91.; Newman S. Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer. Curr Opin Investig Drugs 2007;8(12):1057–66. 28. Owonikoko T.K. and Khuri F.R. Targeting the PI3K/AKT/mTOR Pathway. Am Soc Clin Oncol Educ Book 2013;2013:395–401.; Herzog A., Bian Y., Vander Broek R. et al. PI3K-mTOR inhibitor PF-04691502 anti-tumor activity is enhanced with induction of wild-type TP53 in human xenograft and murine knockout models of head and neck cancer. Clin Cancer Res 2013 May 2.; Jiang T., Zhou C., Gu J. et al. Enhanced therapeutic effect of cisplatin on the prostate cancer in tumor-bearing mice by transfecting the attenuated Salmonella carrying a plasmid co-expressing p53 gene and mdm2 siRNA. Cancer Lett 2013 May 29.; Yabuuchi S., Pai S.G., Campbell N.R. et al. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer Lett 2013;335(1):41–51.; Allay J.A., Steiner M.S., Zhang Y. et al. Adenovirus p16 gene therapy for prostate cancer. World J Urol 2000;18(2):111–20.; Sadeqzadeh E., de Bock C.E. and Thorne R.F. Sleeping Giants: Emerging Roles for the Fat Cadherins in Health and Disease. Med Res Rev 2013 May 29.; Ren M., Hong M., Liu G. et al. Novel FGFR inhibitor ponatinib suppresses the growth of non-small cell lung cancer cells overexpressing FGFR1. Oncol Rep 2013;29(6):2181–90.; Sweeny L., Liu Z., Lancaster W. et al. Inhibition of fibroblasts reduced head and neck cancer growth by targeting fibroblast growth factor receptor. Laryngoscope 2012;122(7):1539–44.; https://ogsh.abvpress.ru/jour/article/view/11
-
4Academic Journal
Authors: Брауншвейг, Т., Левандровски, А., Смеетс, Д., Болотин, М.
Subject Terms: ПЛОСКОКЛЕТОЧНЫЙ РАК, ГОЛОВА И ШЕЯ, ПЛОСКОКЛЕТОЧНЫЙ РАК ГОЛОВЫ И ШЕИ, ПЛОСКОКЛЕТОЧНЫЙ РАК РОТОГЛОТКИ, ВИРУС ПАПИЛЛОМЫ ЧЕЛОВЕКА, МУТАЦИИ, ИССЛЕДОВАНИЕ
File Description: text/html
-
5Academic Journal
Source: Опухоли головы и шеи.
Subject Terms: ПЛОСКОКЛЕТОЧНЫЙ РАК, ГОЛОВА И ШЕЯ, ПЛОСКОКЛЕТОЧНЫЙ РАК ГОЛОВЫ И ШЕИ, ПЛОСКОКЛЕТОЧНЫЙ РАК РОТОГЛОТКИ, ВИРУС ПАПИЛЛОМЫ ЧЕЛОВЕКА, МУТАЦИИ, ИССЛЕДОВАНИЕ, 3. Good health
File Description: text/html
-
6Academic Journal
Authors: Голубев П.В., Болотина Л.В., Геворков А.Р., Дешкина Т.И., Бойко А.В., Каприн А.Д.
Source: Siberian Journal of Oncology
Subject Terms: squamous cell carcinoma, Oropharyngeal carcinoma, human papillomavirus, induction chemotherapy, toxicity, survival, плоскоклеточный рак ротоглотки, вирус папилломы человека, индукционная химиотерапия, токсичность, выживаемость
Availability: https://repository.rudn.ru/records/article/record/101947/
-
7Academic Journal
Authors: Пхешхова Б.Г., Мудунов А.М., Азизян Р.И., Пак М.Б., Ищенко К.Б.
Source: Опухоли головы и шеи
Subject Terms: Oropharyngeal squamous cell carcinoma, human papillomavirus, p16, head and neck tumors, плоскоклеточный рак ротоглотки, вирус папилломы человека, р16, опухоли головы и шеи
Availability: https://repository.rudn.ru/records/article/record/85671/
